ArticleBioinformatics advances2025
CoDNet: controlled diffusion network for structure-based drug design.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Structure-based drug design (SBDD) holds promising potential to design ligands with high-binding affinity and rationalize their interaction with targets. By utilizing geometric knowledge of the three-dimensional (3D) structures of target binding sites, SBDD enhances the efficacy and selectivity of therapeutic agents by optimizing binding interactions at the molecular level. Here, we present CoDNet, a novel approach that combines the conditioning capabilities of ControlNet with the potency of the diffusion model to create generative frameworks for molecular compound design. This proposed method pioneers the application of ControlNet in diffusion model-based drug development. Its ability to generate drug-like compounds from 3D conformations is prominent due to its capability to bypass Open Babel post-processing and integrate bond details and molecular information. Results: For the gold standard QM9 dataset, CoDNet outperforms existing state-of-the-art methods with a validity rate of 99.02%. This competitive performance underscores the precision and efficacy of CoDNet's drug design, establishing it as a significant advancement with great potential for enhancing drug development initiatives. Availability and implementation: https://github.com/CoDNet1/EDM_Custom.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.